Participants achieving ≥20% weight reduction showed significant improvements in measures.
All tirzepatide treatment groups experienced significant enhancements in compared to placebo.
Incremental improvements in quality of life measures were observed with greater degrees of weight reduction, starting from ≥5%.
Participants with ≥20% weight reduction had the largest increases in scores for physical and mental health components.
Individuals with baseline physical and psychosocial limitations reported greater improvements in health-related quality of life than those without such limitations.
Simplified
AIMS: The SURMOUNT-1 trial investigated effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on body weight in participants with obesity or overweight. This analysis evaluated changes in (PROs) assessing physical function, psychosocial well-being, and overall health aspects of participants' (HRQoL) in SURMOUNT-1.
METHODS: PRO instruments included the Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQOL-Lite-CT), Short Form Survey-36 version 2 (SF-36v2) and EQ-5D-5L. Scores were analysed by treatment group and by categorical degree of weight reduction group: >0 to <5%, ≥5 to <10%, ≥10 to <20% and ≥20%. Relevant PROs were evaluated for participants with or without physical or psychosocial limitations at baseline, as measured by Patient Global Impression of Status for physical activity (PGIS) and Patient Health Questionnaire-2 (PHQ-2), respectively.
RESULTS: All tirzepatide groups demonstrated significant improvements in PRO scores versus placebo. There was a consistent trend of incremental PRO improvement with greater degrees of weight reduction, starting from ≥5% weight reduction. Participants achieving ≥20% weight reduction demonstrated the greatest changes from baseline to week 72 (SF-36v2 Physical Component Summary, 4.60; SF-36v2 Mental Component Summary, 0.80; IWQOL-Lite CT Total score, 24.7). Those with baseline physical and psychosocial limitations experienced greater improvements than those without.
CONCLUSIONS: Tirzepatide treatment was associated with improved HRQoL compared to placebo in people with overweight or obesity. Higher percentages of weight reduction were associated with greater improvements. Clinical trial registration number for SURMOUNT-1: NCT04184622.
Key numbers
24.7
IWQOL-Lite-CT Total Score Change
Change from baseline to week 72 in tirzepatide-treated participants.
4.60
SF-36v2 Physical Component Summary Change
Change from baseline to week 72 in tirzepatide-treated participants.
0.80
SF-36v2 Mental Component Summary Change
Change from baseline to week 72 in tirzepatide-treated participants.
Full Text
We can’t show the full text here under this license.
Kimberly A. Gudzune was engaged in this research as a private advisor and not in her capacity as a faculty member of Johns Hopkins University. She was not financially compensated for the advising service related to this work and did not receive payment or honorarium in support of authoring activities. Kimberly A. Gudzune served as medical director for the American Board of Obesity Medicine. She has received personal fees from Johns Hopkins ACG System and PRI‐MED; personal fees for participation on advisory boards for Eli Lilly and Company and Novo Nordisk; and travel support from Eli Lilly and Company and Novo Nordisk. Her institution has received grant funding from Novo Nordisk. Since conduct of this work, Kimberly A. Gudzune joined the American Board of Obesity Medicine Foundation as an employee. Adam Stefanski, Dachuang Cao, Donna Mojdami, Fangyu Wang, Nadia Ahmad and Jiat Ling Poon are employees and shareholders of Eli Lilly and Company.
PubMed
Weekly GLP-1 Therapies Brief
You found one interesting study. We’ll send the next 7.
Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.
